Nevro (NVRO) Scheduled to Post Earnings on Tuesday

Nevro (NYSE:NVRO) will be issuing its quarterly earnings data after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of ($1.02) per share for the quarter. Nevro has set its FY 2024 guidance at EPS and its Q1 2024 guidance at EPS.Persons interested in registering for the company’s earnings conference call can do so using this link.

Nevro (NYSE:NVRO) last released its quarterly earnings results on Wednesday, February 21st. The medical equipment provider reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.35. The business had revenue of $116.18 million for the quarter, compared to the consensus estimate of $115.93 million. Nevro had a negative net margin of 21.69% and a negative return on equity of 30.22%. On average, analysts expect Nevro to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Nevro Price Performance

Shares of NYSE:NVRO opened at $11.43 on Tuesday. The company has a current ratio of 6.37, a quick ratio of 4.94 and a debt-to-equity ratio of 0.72. Nevro has a 1 year low of $11.26 and a 1 year high of $29.77. The firm has a fifty day moving average price of $13.82 and a 200 day moving average price of $16.51.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Mizuho decreased their price target on Nevro from $20.00 to $16.00 and set a “neutral” rating for the company in a research note on Thursday, April 11th. Robert W. Baird dropped their price target on shares of Nevro from $23.00 to $19.00 and set a “neutral” rating on the stock in a research report on Thursday, February 22nd. Oppenheimer downgraded shares of Nevro from an “outperform” rating to a “market perform” rating in a report on Thursday, February 22nd. StockNews.com upgraded shares of Nevro from a “sell” rating to a “hold” rating in a research note on Friday, March 1st. Finally, Royal Bank of Canada cut their target price on shares of Nevro from $18.00 to $16.00 and set a “sector perform” rating for the company in a research report on Monday, April 15th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $21.23.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.